Status:

UNKNOWN

The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions:

Surgical Resection

HCC

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world with major occurrences in eastern Asian countries such as China. HCC is the third leading cause of cancer-related deaths i...

Detailed Description

The Barcelona Clinic Liver Cancer staging system (BCLC) is one of the more recognized staging criteria and has been recommended by the European Association for the Study of Liver and the American Asso...

Eligibility Criteria

Inclusion

  • Ages 18-75 with no gender, ethnicity, religion, or geographical restrictions.
  • Diagnosed HCC patient.
  • The following criteria will be used for the evaluation of tumor resectability and adequate remaining liver volume: ≥ 30% remaining liver volume/total liver volume for non-hepatitis patients; ≥ 40% remaining liver volume/total liver volume for hepatitis patients.
  • Imaging examination with no cancer embolus above the secondary branch of the portal vein.
  • New lesions found five years after liver cancer treatment.
  • Child-Pugh A or B grade liver function.
  • No concurrent malignancies in other systems.
  • Informed subjects who fully understand and willingly cooperate with the test program with signed relevant documents.

Exclusion

  • Suffer from other malignancies.
  • Have received any other liver cancer treatments.
  • Pathological diagnosis as non-HCC.
  • Experience large blood vessel invasion, distant metastases, or unresectable liver cancer.
  • One or more organ failures.
  • Child-Pugh C grade liver function.
  • Incomplete surgical resection or TILA-TACE.

Key Trial Info

Start Date :

November 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

230 Patients enrolled

Trial Details

Trial ID

NCT03314532

Start Date

November 1 2017

End Date

December 31 2022

Last Update

October 19 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Second Affiliated Hospital Zhejiang University School of Medicine

Hanzhou, Zhejiang, China, 310009

The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma | DecenTrialz